Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889092 | 1.00 | CES1 (0.52) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL12083377 | 0.84 | CES1 (0.50) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL21310 | 0.81 | CES1 (0.56) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL9105008 | 0.81 | CES1 (0.56) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL1606581 | 0.81 | CES1 (0.56) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL11341422 | 0.81 | CES1 (0.56) | CES1SRCTSHRCES2ALDH1A1 | |
| SCHEMBL8223282 | 0.81 | CES1 (0.46) | CES1CES2MAPTCYP2C19CA1 | |
| SCHEMBL9420249 | 0.81 | LMNA (0.40) | SRCTSHRTDP1POLBCYP3A4 | |
| SCHEMBL14889163 | 0.81 | ALOX15 (0.50) | CES1TSHRCES2ALDH1A1POLB | |
| SCHEMBL14889160 | 0.81 | ALOX15 (0.50) | CES1TSHRCES2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586769-B1 | METHOD FOR PRODUCING (1R, 2S)-1-AMINO-2-VINYL CYCLOPROPANE CARBOXYLIC ACID ESTER THAT HAS IMPROVED OPTICAL PURITY | KANEKA CORP (JP) | 2019-01-16 | — | — | EP | disclosed |
| CN-106433480-A | Polishing liquid and method for polishing substrate using the polishing liquid | 日立化成株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-102906064-B | The manufacture method of (1R, 2S)-1-amino-2-vinylcyclopropanecaracidlic acidlic ester that optical purity has been improved | KANEKA CORP. (JP) | 2015-07-29 | — | — | CN | disclosed |
| EP-1363869-B1 | PROCESS FOR THE PREPARATION OF ALKYL BENZOYLACRYLATES | WEYLCHEM LAMOTTE (FR) | 2015-04-08 | — | — | EP | disclosed |
| EP-2586769-A1 | METHOD FOR PRODUCING (1R, 2S)-1-AMINO-2-VINYL CYCLOPROPANE CARBOXYLIC ACID ESTER THAT HAS IMPROVED OPTICAL PURITY | KANEKA CORPORATION (JP) | 2013-05-01 | — | — | EP | disclosed |
| CN-102906064-A | Method for producing (1r, 2s)-1-amino-2-vinyl cyclopropane carboxylic acid ester that has improved optical purity | KANEKA CORP | 2013-01-30 | — | — | CN | disclosed |
| EP-1489088-B1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | NIPPON KAYAKU KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7348318-B2 | α-Amino-N-(diaminophosphinyl)lactam derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-03-25 | — | — | US | disclosed |
| CN-1243709-C | Process for prepn. of alkyl benzoylacrylates | CLARIANT FRANCE SA (FR) | 2006-03-01 | — | — | CN | disclosed |
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1489088-A1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-12-22 | — | — | EP | disclosed |
| CN-1500074-A | Process for prepn. of alkyl benzoylacrylates | 克莱里安特法国公司 | 2004-05-26 | — | — | CN | disclosed |
| WO-2004007417-A1 | ENZYME INHIBITORS | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2004-01-22 | — | — | WO | disclosed |
| EP-1363869-A2 | PROCESS FOR THE PREPARATION OF ALKYL BENZOYLACRYLATES | Clariant (France) S.A. (FR) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002067847-A2 | PROCESS FOR THE PREPARATION OF ALKYL BENZOYLACRYLATES | CLARIANT (FRANCE) (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | DNPEP, PEPD, ANPEP | CES1 1098/4885SRC 3273/4885TSHR 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.